1800-272-662
Shopping Cart 0
countryflagAU
Login

ZyVersa Therapeutics Inc.

Healthcare US ZVSA

0.25USD
-(-%)

Last update at 2026-03-11T14:33:00Z

Day Range

0.250.27
LowHigh

52 Week Range

4.20147.00
LowHigh

Fundamentals

  • Previous Close 0.25
  • Market Cap3.55M
  • Volume3100
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.64493M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-945.81

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -14.04761M -8.08416M -12.68317M
Minority interest - - -
Net income -759.09761M -8.90553M -13.19962M
Selling general administrative 7.61M 5.58M 5.36M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation 0.00987M 0.01M 0.01M
Ebit -13.01306M -7.70438M -11.83306M
Ebitda -13.00320M -7.69398M -11.82266M
Depreciation and amortization 0.00987M 0.01M 0.01M
Non operating income net other - - -
Operating income -13.01306M -7.70438M -11.83306M
Other operating expenses 13.01M 7.70M 11.83M
Interest expense 0.43M 0.82M 0.52M
Tax provision 0.00000M - -
Interest income - - -
Net interest income -0.42754M -0.82137M -0.51645M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 745.05M 0.82M 0.52M
Total revenue 0.00000M 0.00000M 0.00000M
Total operating expenses 13.01M 7.70M 11.83M
Cost of revenue - - -
Total other income expense net -1.03454M -0.37978M -0.85011M
Discontinued operations - - -
Net income from continuing ops -14.04761M -8.08416M -12.68317M
Net income applicable to common shares -14.12262M -8.08416M -12.68317M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 22.11M 118.51M 1.13M 0.69M
Intangible assets 18.65M 100.09M - -
Earning assets - - - -
Other current assets 0.22M 0.23M 0.48M 0.16M
Total liab 11.04M 18.51M 13.63M 9.24M
Total stockholder equity 11.07M 99.99M -12.50014M -8.55771M
Deferred long term liab - - - -
Other current liab 1.75M 2.05M 1.71M 1.94M
Common stock 0.00040M 0.00090M 0.00024M 0.00024M
Capital stock 0.00041M 0.00090M 0.00024M 0.00024M
Retained earnings -103.21912M -4.92118M -52.89682M -44.81266M
Other liab - 10.66M 0.33M 0.33M
Good will 0.00000M 11.90M - -
Other assets - 0.00000M 0.29M 0.31M
Cash 3.14M 5.90M 0.33M 0.17M
Cash and equivalents - - - -
Total current liabilities 10.19M 8.19M 13.63M 7.56M
Current deferred revenue - - 0.77M 1.18M
Net debt -3.12902M -5.79344M 8.82M 3.64M
Short term debt 0.00866M 0.11M 9.15M 2.13M
Short long term debt - - 9.15M 2.13M
Short long term debt total 0.00866M 0.11M 9.15M 3.82M
Other stockholder equity 114.29M 104.91M 40.40M 36.25M
Property plant equipment - 0.12M 0.03M 0.04M
Total current assets 3.35M 6.36M 0.81M 0.34M
Long term investments - - - -
Net tangible assets - -12.31837M -12.83147M -8.88904M
Short term investments - - - -
Net receivables - - - -
Long term debt - - - 1.69M
Inventory - - - -
Accounts payable 8.43M 6.03M 2.00M 2.31M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.00100M - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.10M 0.05M 0.29M 0.31M
Deferred long term asset charges - - - -
Non current assets total 18.76M 112.14M 0.31M 0.35M
Capital lease obligations 0.00866M 0.11M - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments - - -
Change to liabilities 4.54M -0.31186M -0.60147M
Total cashflows from investing activities - - -
Net borrowings - 5.23M 1.69M
Total cash from financing activities 1.87M 5.23M 4.56M
Change to operating activities 1.12M -0.70845M 3.71M
Net income -14.04761M -8.08416M -12.68317M
Change in cash 0.37M 0.15M -0.54976M
Begin period cash flow 0.33M 0.17M 0.72M
End period cash flow 0.70M 0.33M 0.17M
Total cash from operating activities -1.49464M -5.07609M -5.10983M
Issuance of capital stock 1.96M 0.00000M 3.00M
Depreciation 0.00987M 0.01M 0.01M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -
Other cashflows from financing activities 1.87M 5.23M 1.56M
Change to netincome 3.53M 3.70M 4.16M
Capital expenditures 0.00000M 0.00000M 0.00000M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 8.29M -1.02032M 3.11M
Stock based compensation 3.52M 4.14M 3.83M
Other non cash items 0.73M 0.32M 0.29M
Free cash flow -1.49464M -5.07609M -5.10983M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ZVSA
ZyVersa Therapeutics Inc.		 - -% 0.25 - - - 0.49 -0.1588
NVO
Novo Nordisk A/S		 0.16 0.41% 38.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.89 0.98% 494.28 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.71 0.48% 775.75 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

ZyVersa Therapeutics Inc.

2200 N. Commerce Parkway, Weston, FL, United States, 33326

Key Executives

Name Title Year Born
Mr. Stephen C. Glover Co-Founder, CEO & Chairman 1960
Mr. Peter Wolfe Sr. VP of Fin. & Admin. 1967
Mr. Nicholas A. LaBella Jr., MS, RPh. Chief Scientific Officer and Sr. VP of R&D 1956
Ms. Melda Uzbil O'connell Sr. VP of Corp. Devel. NA
Ms. Karen A. Cashmere Chief Commercial Officer 1963
Dr. Pablo A. Guzman M.D. Chief Medical Officer & Member of Scientific Advisory Board NA
Mr. Stephen C. Glover Co-Founder, Chairman, CEO & President 1960
Mr. Peter Wolfe CFO & Secretary 1968
Ms. Karen A. Cashmere Chief Commercial Officer 1952
Ms. Melda Uzbil O'connell Senior Vice President of Corporate Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.